---
title: Mayo Clinic's Senolytic Combo Increased Bone Density in 12 Weeks
slug: "senolytics-bone-density-mayo-clinic"
description: Mayo Clinic Phase 2 trial shows Dasatinib + Quercetin improves bone health
date: '2026-02-17'
category: Clinical Trial
featured: false
author: Longevity Leak Research Team
studyUrl: https://www.p05.org/longevity-treatments-in-human-trials-2024-2025/
published: true
---
# Mayo Clinic's Senolytic Combo Increased Bone Density in 12 Weeks

## What This Trial Is Pointing To

A phase-2 style signal suggests that senolytic combinations may affect bone remodeling biomarkers and potentially bone-density trajectories in selected older cohorts.

That is clinically interesting because fracture risk and frailty progression are major aging drivers, and current prevention options are often underused or poorly tolerated.

## Why It Matters

If senescent-cell burden is a true modifiable contributor to bone decline, senolytics could become a targeted adjunct in high-risk groups. But today, this remains a research-level hypothesis with early human support rather than settled clinical standard.

## Practical Interpretation

For current decision-making, proven bone-health interventions still carry stronger evidence:

- progressive resistance and impact loading
- protein adequacy and vitamin D status correction
- fall-risk reduction and medication review

Experimental senolytic strategies should be interpreted cautiously and with specialist oversight.
Protocol quality also matters: timing, cycle design, and clinical context can change both safety and expected benefit.

Related pages:

- [Fisetin](/supplements/fisetin)
- [Quercetin](/supplements/quercetin)
- [Osteopenia and Fragility](/conditions/osteopenia-and-fragility)

## Evidence Limits and What We Still Need

Evidence remains limited by cohort size, trial duration, and endpoint maturity. We need longer studies with hard fracture outcomes, durability follow-up, and clearer adverse-event characterization across comorbidity profiles.

## Sources

1. [Human-trial tracking summary](https://www.p05.org/longevity-treatments-in-human-trials-2024-2025/)
2. [Senolytics clinical translation review (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40437670/)
